日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Structural and biochemical differences between non-catalytic and catalytic antibodies

非催化抗体和催化抗体在结构和生化方面的差异

期刊:MAbs
影响因子:7.3
doi:10.1080/19420862.2025.2503978
Uda, Taizo; Kato, Ryuichi; Shigeta, Yasuteru; Hirota, Shun; Kobayashi, Jun; Yoshida, Hisashi; Tsuyuguchi, Masato; Hengphasatporn, Kowit; Tsujita, Moe; Taguchi, Hiroaki; Hifumi, Emi
发表日期：2025
文献求助 收藏

Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study)

方案：在对甲氨蝶呤反应不足的类风湿性关节炎患者中，菲戈替尼联合甲氨蝶呤治疗与菲戈替尼单药治疗的比较：一项多中心、前瞻性、开放标签、随机对照试验（FAITHFUL 研究）

期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0322621
Akiyama, Mitsuhiro; Hidaka, Toshihiko; Kaneko, Motohide; Ito, Satoshi; Taguchi, Hiroaki; Ishii, Tomonori; Asai, Shuji; Hirata, Shintaro; Ikeda, Kei; Suzuki, Katsuya; Kato, Naoki; Kaneko, Yuko
关节炎
发表日期：2025
文献求助 收藏

Clinical Images: Epistaxis may be a warning sign of lymphoproliferative disorder during methotrexate treatment for dermatomyositis

临床影像：鼻出血可能是甲氨蝶呤治疗皮肌炎期间淋巴增生性疾病的预警信号。

期刊:ACR Open Rheumatology
影响因子:2.8
doi:10.1002/acr2.11647
Ishigaki, Sho; Kajio, Nobuhiko; Okayama, Mikio; Orikasa, Hideki; Tanaka, Shoko; Yoshikawa, Noritada; Taguchi, Hiroaki
信号转导
发表日期：2024
文献求助 收藏

Direct conversion of a general antibody to its catalytic antibody and corresponding applications -Importance and role of Pro95 in CDR-3

通用抗体直接转化为催化抗体及其相应应用——Pro95在CDR-3中的重要性和作用

期刊:Proceedings of the Japan Academy Series B-Physical and Biological Sciences
影响因子:4.6
doi:10.2183/pjab.99.010
Hifumi, Emi; Taguchi, Hiroaki; Nonaka, Tamami; Uda, Taizo
发表日期：2023
文献求助 收藏

Obtaining Highly Active Catalytic Antibodies Capable of Enzymatically Cleaving Antigens.

获得能够酶促裂解抗原的高活性催化抗体

期刊:International Journal of Molecular Sciences
影响因子:4.9
doi:10.3390/ijms232214351
Nonaka Tamami, Taguchi Hiroaki, Uda Taizo, Hifumi Emi
其它
发表日期：2022
文献求助 收藏

A new algorithm to convert a normal antibody into the corresponding catalytic antibody.

一种将普通抗体转化为相应催化抗体的新算法

期刊:Science Advances
影响因子:12.5
doi:10.1126/sciadv.aay6441
Hifumi Emi, Taguchi Hiroaki, Tsuda Haruna, Minagawa Tetsuro, Nonaka Tamami, Uda Taizo
其它
发表日期：2020
文献求助 收藏

New technologies to introduce a catalytic function into antibodies: A unique human catalytic antibody light chain showing degradation of β-amyloid molecule along with the peptidase activity

将催化功能引入抗体的新技术：一种独特的人类催化抗体轻链，可降解β-淀粉样蛋白分子并具有肽酶活性。

期刊:FASEB BioAdvances
影响因子:2
doi:10.1096/fba.1025
Hifumi, Emi; Taguchi, Hiroaki; Toorisaka, Eiichi; Uda, Taizo
发表日期：2019
文献求助 收藏

Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study

红细胞甲氨蝶呤-多聚谷氨酸水平与甲氨蝶呤治疗类风湿性关节炎患者的疗效和肝毒性的相关性：一项为期76周的前瞻性研究

期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2016-000363
Takahashi, Chihiro; Kaneko, Yuko; Okano, Yutaka; Taguchi, Hiroaki; Oshima, Hisaji; Izumi, Keisuke; Yamaoka, Kunihiro; Takeuchi, Tsutomu
关节炎
毒理研究
红细胞
细胞生物学
发表日期：2017
文献求助 收藏

Metal-dependent amyloid β-degrading catalytic antibody construct

金属依赖性β-淀粉样蛋白降解催化抗体构建体

期刊:Journal of Biotechnology
影响因子:3.9
doi:10.1016/j.jbiotec.2014.03.026
Nishiyama, Yasuhiro; Taguchi, Hiroaki; Hara, Mariko; Planque, Stephanie A; Mitsuda, Yukie; Paul, Sudhir
蛋白降解
发表日期：2014
文献求助 收藏

Contribution of histone N-terminal tails to the structure and stability of nucleosomes

组蛋白N端尾部对核小体结构和稳定性的贡献

期刊:FEBS Open Bio
影响因子:2.8
doi:10.1016/j.fob.2013.08.007
Wakana Iwasaki,Yuta Miya, Naoki Horikoshi, Akihisa Osakabe, Hiroyuki Taguchi, Hiroaki Tachiwana, Takehiko Shibata, Wataru Kagawa, Hitoshi Kurumizaka
炎性小体
发表日期：2013
文献求助 收藏